Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 1.00 |
| ▸ | RARG | P13631 | 14/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | RXRA | P19793 | 7/20 | 0.57 |
| ▸ | RARA | P10276 | 12/20 | 0.56 |
| ▸ | RXRB | P28702 | 4/20 | 0.54 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | BLVRB | P30043 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354207 | 1.00 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL30477013 | 1.00 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL165751 | 1.00 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL165750 | 1.00 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL29613246 | 1.00 | RARB (1.00) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL8519542 | 0.89 | RARB (0.81) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL5080286 | 0.83 | RARB (0.71) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL23752347 | 0.79 | RARB (0.65) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL23752176 | 0.79 | RARB (0.65) | RARBRARGCYP26A1CYP3A4RXRA | |
| SCHEMBL20609262 | 0.77 | RARB (0.63) | RARBRARGCYP26A1CYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144683-A1 | METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2010-06-10 | — | — | US | claimed |
| EP-1891944-A1 | Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases | Association pour la recherche à l'IGBMC (ARI) (FR) | 2008-02-27 | — | — | EP | claimed |
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | Clementia Pharmaceuticals Inc. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | Clementia Pharmaceuticals Inc. (CA) | 2019-09-12 | — | — | US | disclosed |
| WO-2018090137-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | Clementia Pharmaceuticals Inc. (CA) | 2018-05-24 | — | — | WO | disclosed |
| EP-2046309-B1 | USE OF VITAMIN D3 AGONIST MC903 IN A MAMMALIAN MODEL FOR ATOPIC DISEASES | ASS POUR LA RECH A L IGBMC ARI (FR) | 2010-12-15 | — | — | EP | disclosed |
| US-20100144683-A1 | METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2046309-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | Association pour la recherche à l'IGBMC (ARI) (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012645-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-6331570-B1 | PREVENTION OF SPONTANEOUS SQUAMOUS CELL CARCINOMA IN IMMUNOCOMPROMISED HUMAN TRANSPLANT PATIENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | UTRN, VHL, SOST | RARB 1620/4885RARG 1720/4885CYP26A1 463/4885 |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | UTRN, VHL, SOST | RARB 1620/4885RARG 1720/4885CYP26A1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.